Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways

Stopped early

Conditions studied: Chronic Disease, Endocrine System Disease, Cardiovascular Disease, Respiratory Tract Disease, CNS Metabolic Disorders

In brief

This observation will look at patient care decisions of the primary healthcare provider utilizing the results of the DNA testing of patients' metabolic pathways using 2C19, 2C9, 2D6, 3A4, Factor II, Factor V and MTHFR and VKORC1. Findings of the data collection will be published to optimize the benefits of pharmacogenomics testing and publish health outcomes.

Key facts

Study ID

NCT02525887

Run by

Bracane Company

People needed

80

Starts

2015-07-01

Expected to finish

2016-01-01

Last updated by the study team

2016-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult male or female patients age 18 or older
• Prescribed at least one medication with in any of the metabolic pathways being assessed will be enrolled in the study.
• Completed DNA testing for the pathways under review for this observation.

You may not qualify if…

• Anticipated life expectancy less than 1 month.
• Employee of the investigator, with direct involvement in the proposed study or other studies under the direction of the investigator, as well as immediate family members or the employee or primary care provider.

Where it is running

• Sevierville Foot and Ankle Clinic — Sevierville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.